Thus, as described herein, the adoptive transfer of naïve, tumor antigen-specific CD8+ T cells in this model prior to vaccine and IL-21 + low-dose IL-2 therapy may provide a better opportunity to study methods of generating both effector and long-term anti-tumor memory T-cell function than can be achieved with highly activated IVS T cells. The gene discussed is IL2; the disease is neoplasm.